The Bigger Picture And Global Innovation Hotspots
Executive Summary
Focusing too much on the US provides a blinkered view of the industry and prevents access to the myriad opportunities on offer globally.
You may also be interested in...
The Drug Hunter’s Assistant: Accelerating Drug Discovery With AI
The hype around Artificial Intelligence has been deafening in recent years, but real progress can only come when drug discovery culture and regulators catch up with the technology.
PharmAI – Industry Is Smartening Up To Potential Of Artificial Intelligence
AstraZeneca’s pact with the UK-based artificial intelligence leader BenevolentAI, in April 2019, is one component in a string of recent deals that have highlighted big pharma’s desire to embed AI and machine learning within the R&D process. In total, 13 such collaborations have been tracked in the past 24 months, according to the Strategic Transactions database.
France: A European Leader In Rare Diseases
France has long been a European leader in rare diseases, from its scientific research and academic hospitals, through to patient advocacy and regulatory reforms that have encouraged R&D. Its biotech and pharmaceutical industries are now leading the way, discovering the next generation of therapies for patients that are often overlooked.